# NBIX — Neurocrine Biosciences · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** NBIX  
**Sources:** 19  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-nbix-neurocrine-biosciences-catalysts-narrative-risks-5961

---

## Neurocrine Biosciences (NBIX) — Point-in-Time Review (as of 2026-10-04)

### Recent catalysts (last ~1–3 months)

**Q2 2026 earnings (reported July 30, 2026)** is the dominant recent catalyst. Total revenue rose 39% year-over-year to $959 million, well above the Zacks Consensus Estimate of ~$901.5 million, and adjusted (non-GAAP) EPS came in at $2.85 versus consensus estimates ranging from ~$2.10–$2.26 depending on the provider [[1]](https://www.biospace.com/press-releases/neurocrine-biosciences-reports-second-quarter-2026-financial-results), [[2]](https://www.msn.com/en-us/money/other/can-nbix-s-q2-beat-and-higher-ingrezza-guidance-drive-more-growth/ar-AA2azW7X), [[12]](https://finance.yahoo.com/healthcare/articles/nbixs-q2-beat-higher-ingrezza-151800369.html), [[14]](https://public.com/stocks/nbix/earnings). This beat was broad-based:

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-nbix-neurocrine-biosciences-catalysts-narrative-risks-5961 (free to sign up)._
